相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma
Tressie Herrmann et al.
ONCOLOGY (2022)
Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
Shinkichi Takamori et al.
LUNG CANCER (2021)
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
Edoardo Lenci et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
Shijia Zhang et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2021)
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors
Ali Raza Khaki et al.
CANCER (2020)
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
Eiki Ichihara et al.
LUNG CANCER (2020)
Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2020)
Inter-rater reliability in performance status assessment between clinicians and patients: a systematic review and meta-analysis
Ronald Chow et al.
BMJ SUPPORTIVE & PALLIATIVE CARE (2020)
HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany.
Andreas Dietz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice
Mary K. Nesline et al.
CLINICAL THERAPEUTICS (2020)
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation
Charlotte Couchoud et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
Ye Li et al.
FRONTIERS IN ONCOLOGY (2020)
Performance Status Restriction in Phase III Cancer Clinical Trials
Joseph Abi Jaoude et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
Seigo Minami et al.
WORLD JOURNAL OF ONCOLOGY (2020)
Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1
Norimitsu Kasahara et al.
ANTICANCER RESEARCH (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Lea Gauci et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
Sanna Iivanainen et al.
ESMO OPEN (2019)
Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
Seigo Minami et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
Seigo Minami et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective
Helmy M. Guirgis
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
Frederic Bigot et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
Yuko Oya et al.
ONCOTARGET (2017)
Serum lactate dehydrogenase is a predictor of poor survival in malignant
Dong Gao et al.
PANMINERVA MEDICA (2017)
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati et al.
BRITISH JOURNAL OF CANCER (2017)
Statistical controversies in clinical research: the importance of importance
A. Gleiss et al.
ANNALS OF ONCOLOGY (2016)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Pembrolizumab in classical Hodgkin's lymphoma
Joseph Maly et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein
Shenying Fang et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
Fausto Petrelli et al.
ACTA ONCOLOGICA (2015)
C-Reactive Protein As a Marker of Melanoma Progression
Shenying Fang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists
Yu Jung Kim et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A catalogue of reporting guidelines for health research
I. Simera et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
分享论文
